ATE444961T1 - Verbindungen vom hydrazidtyp und deren verwendung in pharmazeutischen zusammensetzungen zur behandlung von herzkreislauferkrankungen - Google Patents

Verbindungen vom hydrazidtyp und deren verwendung in pharmazeutischen zusammensetzungen zur behandlung von herzkreislauferkrankungen

Info

Publication number
ATE444961T1
ATE444961T1 AT05717518T AT05717518T ATE444961T1 AT E444961 T1 ATE444961 T1 AT E444961T1 AT 05717518 T AT05717518 T AT 05717518T AT 05717518 T AT05717518 T AT 05717518T AT E444961 T1 ATE444961 T1 AT E444961T1
Authority
AT
Austria
Prior art keywords
hydrazide
treatment
pharmaceutical compositions
cardiovascular diseases
type compounds
Prior art date
Application number
AT05717518T
Other languages
English (en)
Inventor
Gerard Marguerie
Eric Malaud
Original Assignee
Clinigenetics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clinigenetics filed Critical Clinigenetics
Application granted granted Critical
Publication of ATE444961T1 publication Critical patent/ATE444961T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/16—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/72—Hydrazones
    • C07C251/86—Hydrazones having doubly-bound carbon atoms of hydrazone groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D333/70—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Furan Compounds (AREA)
  • Pyridine Compounds (AREA)
AT05717518T 2004-01-30 2005-01-31 Verbindungen vom hydrazidtyp und deren verwendung in pharmazeutischen zusammensetzungen zur behandlung von herzkreislauferkrankungen ATE444961T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0400913A FR2865732B1 (fr) 2004-01-30 2004-01-30 Composes de type hydrazide et leur utilisation dans des compositions pharmaceutiques pour le traitement des maladies cardiovasculaires
PCT/FR2005/000199 WO2005082882A1 (fr) 2004-01-30 2005-01-31 Composes de type hydrazide et leur utilisation dans des compositions pharmaceutiques pour le traitement des maladies cardiovasculaires

Publications (1)

Publication Number Publication Date
ATE444961T1 true ATE444961T1 (de) 2009-10-15

Family

ID=34746342

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05717518T ATE444961T1 (de) 2004-01-30 2005-01-31 Verbindungen vom hydrazidtyp und deren verwendung in pharmazeutischen zusammensetzungen zur behandlung von herzkreislauferkrankungen

Country Status (15)

Country Link
US (1) US20070161697A1 (de)
EP (2) EP1709027B1 (de)
JP (1) JP5047629B2 (de)
CN (1) CN100588655C (de)
AT (1) ATE444961T1 (de)
AU (1) AU2005217174B2 (de)
BR (1) BRPI0507248A (de)
CA (1) CA2554439A1 (de)
DE (1) DE602005017007D1 (de)
DK (1) DK2113502T3 (de)
ES (2) ES2398479T3 (de)
FR (1) FR2865732B1 (de)
PT (2) PT1709027E (de)
WO (1) WO2005082882A1 (de)
ZA (1) ZA200606909B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006132583A1 (en) * 2005-06-07 2006-12-14 Innate Pharmaceuticals Ab Method and means for preventing and inhibiting respiratory disease, atherosclerosis and osteoporosis caused by chlamydia pneumoniae infection
EP2338879A1 (de) 2009-12-15 2011-06-29 Arteria Neuartige Phenylhydrazon-Derivate und deren pharmazeutische Verwendung
WO2012027548A1 (en) * 2010-08-25 2012-03-01 The Feinstein Institute For Medical Research Compounds and methods for prevention and treatment of alzheimer's and other diseases
CN103044284A (zh) * 2011-10-13 2013-04-17 南京大学 香草酸酰腙类衍生物及其制备和用途
US9526720B2 (en) 2012-08-17 2016-12-27 The Broad Institute, Inc. Modulators of hepatic lipoprotein metabolism
CN103613514B (zh) * 2013-10-30 2015-05-13 西北师范大学 荧光比色识别氰根离子的有机双金属凝胶及其制备和应用
CN104860866B (zh) * 2015-05-25 2018-07-17 厦门大学 5-(取代碳酰氨基)-1h-吲哚-2-碳酰肼衍生物及其制备方法和应用
CN104829597B (zh) * 2015-05-25 2018-07-17 厦门大学 1h-吲哚-2-碳酰肼衍生物及其制备方法和用途
CN105348170B (zh) * 2015-11-06 2019-02-05 厦门大学 1-(2-(碳酰肼取代基团)-1h-吲哚-5-基)-3-取代脲衍生物及制备方法
AU2017375687B2 (en) 2016-09-26 2023-09-14 Qingdao Primedicine Pharmaceutical Co., Ltd. N-methyl-D-aspartate receptor allosteric modulators and methods for their use
PL233208B1 (pl) * 2018-09-17 2019-09-30 Politechnika Wroclawska Iminowe pochodne aldehydów salicylowych i hydrazydu kwasu 4-hydroksybenzoesowego oraz sposób ich wytwarzania
EP4392025A1 (de) * 2021-10-06 2024-07-03 The Research Foundation for The State University of New York Gegen die synthese von pilzsphingolipiden gerichtete pilzbekämpfungsmittel

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB762187A (en) * 1952-10-09 1956-11-28 Bayer Ag Metal complexes of hydrazide-hydrazones and process for producing the same
JPS4819628B1 (de) * 1969-01-07 1973-06-14
US3859281A (en) * 1971-07-01 1975-01-07 American Home Prod 2,6-dichlorobenzylidenehydrazides
US3829492A (en) * 1972-02-04 1974-08-13 Rohm & Haas Fungicidal salicylaldehyde hydrazones and azines
US3963480A (en) * 1973-04-11 1976-06-15 Sterling Drug Inc. Herbicidal pyrrole-2-carboxamides
JPS62501709A (ja) * 1985-02-11 1987-07-09 ジ・アップジョン・カンパニ− 駆虫薬ピリジニル・アシルヒドラゾン、その使用方法および組成物
US5424333A (en) * 1985-10-21 1995-06-13 Rohm And Haas Company Anthelmintic N'-substituted-N,N'-disubstitutedhydrazines
US6005113A (en) * 1996-05-15 1999-12-21 Molecular Probes, Inc. Long wavelength dyes for infrared tracing
JPH11106371A (ja) * 1997-07-04 1999-04-20 Nisshin Flour Milling Co Ltd アシルヒドラゾン誘導体
JP2001233767A (ja) * 2000-02-25 2001-08-28 Shionogi & Co Ltd アポａｉ発現亢進剤
WO2002102301A2 (en) * 2000-12-07 2002-12-27 Cytovia, Inc. Substituted indole-2-carboxylic acid benzylidene-hydrazides and analogs as activators of caspases and inducers of apoptosis and the use thereof
US20040110963A1 (en) * 2001-01-22 2004-06-10 Kaspar Burri Novel hydrazones
DE20108608U1 (de) * 2001-05-23 2001-08-09 Wella Ag, 64295 Darmstadt 2,5-Diamino-benzaldehyd-Derivate und diese Verbindungen enthaltende Färbemittel
EP1462105A1 (de) * 2003-03-28 2004-09-29 Procorde GmbH Aktivierungs-spezifische Inhibitoren von NF-kB und Methode zur Behandlung entzündlicher Prozesse be kardiovaskulären Erkrankungen
DE10348022A1 (de) * 2003-10-15 2005-05-25 Imtm Gmbh Neue Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
JP5591469B2 (ja) * 2006-05-31 2014-09-17 持田製薬株式会社 多重リスク患者の心血管イベント発症予防用組成物

Also Published As

Publication number Publication date
CN100588655C (zh) 2010-02-10
EP1709027B1 (de) 2009-10-07
AU2005217174B2 (en) 2010-04-01
ES2334574T3 (es) 2010-03-12
BRPI0507248A (pt) 2007-06-26
JP2007519691A (ja) 2007-07-19
DE602005017007D1 (de) 2009-11-19
US20070161697A1 (en) 2007-07-12
CA2554439A1 (fr) 2005-09-09
DK2113502T3 (da) 2013-02-18
ES2398479T3 (es) 2013-03-19
FR2865732A1 (fr) 2005-08-05
AU2005217174A1 (en) 2005-09-09
FR2865732B1 (fr) 2007-10-12
PT1709027E (pt) 2010-01-13
EP1709027A1 (de) 2006-10-11
ZA200606909B (en) 2007-12-27
PT2113502E (pt) 2013-02-15
WO2005082882A1 (fr) 2005-09-09
CN1950356A (zh) 2007-04-18
EP2113502B1 (de) 2012-11-14
EP2113502A1 (de) 2009-11-04
JP5047629B2 (ja) 2012-10-10

Similar Documents

Publication Publication Date Title
ATE444961T1 (de) Verbindungen vom hydrazidtyp und deren verwendung in pharmazeutischen zusammensetzungen zur behandlung von herzkreislauferkrankungen
IS7170A (is) Bensóþíasepín og bensóþíadíasepínafleiður með tálmavirkni gegn dausgarnargallsýruflutningi (ileal bile acid transport, IBAT) til að meðhöndla fitudreyra
PE20040898A1 (es) Nuevos compuestos derivados de pirimidina
ATE369337T1 (de) Neue bizyklische verbindungen
NO20065902L (no) 3-{4-(pyridin-3-yl)fenyl}-5-(1H-,1,2,3-triazol-1-ylmetyl)-1,3-oksazolidin-2-oner som antibakterielle midler
DE602004011255D1 (de) Phosphinsäurederivate, inhibitoren von beta-sekretase zur behandlung von alzheimer-krankheit
RU2008129723A (ru) Ингибиторы ccr9 активности
DE50011034D1 (de) N-substituierte 4-aminopteridine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
MY135954A (en) Crystalline form of (s)-ethoxy-3-4-(2-4-methanesulfonyloxyphenyl ethoxy) phenyl] propanoic acid
DE69400723D1 (de) Verwendung von Pyridoxal-Derivaten zur Herstellung eines Arzneimittels zur Behandlung des Katarakts
DE60002558D1 (de) Derivate der Phosphonsäure zur Inhibierung von Carboxypeptidase B
TW200635911A (en) Sulfanyl substituted phenyl methanones
ATE447953T1 (de) Pharmazeutische zusammensetzungen zur behandlung von leishmaniasis
NO20081103L (no) 9-Aminoklarbonylsubstituerte derivater av glycylcykliner
DE69414396D1 (de) Acylphenylglycin-derivat und dieses als aktivbestandteil enthaltendes vorbeugungs -und heilmittel gegen durch erhöhte collagenaseaktivität verursachte krankheiten
DE60219680D1 (de) Amin-1,2- und -1,3-diolverbindungen und deren verwendung zur behandlung von alzheimer-krankheit
ATE386735T1 (de) Substituierte benzoylureidopyridyl-piperidin- und pyrrolidin-carbons urederivate, verfahren zu deren herstellung und deren v erwendung
ATE538108T1 (de) Thiazolhydrazide und deren verwendung zur behandlung von neurodegenerativen krankheiten
MXPA05013717A (es) Derivados de acido 2-etoxi-2-fenilpropionico para el tratamiento de trastornos de lipido.
ATE493988T1 (de) Pyrimidinderivate enthaltendes medikament
TH68407A (th) 3-ไพริดิล-4-แอริลพิร์โรลที่ถูกแทนที่ และวิธีการรักษาโรคและการป้องกันโรคที่เกี่ยวข้อง
TH84863B (th) สารประกอบ, สารผสมที่มีสารเหล่านี้, การเตรียมสารเหล่านี้ และการใช้สารเหล่านี้
SE9904416D0 (sv) Crystalline form
TH51768B (th) สารประกอบคาร์บาฟีเนม การใช้ของสารดังกล่าว และสารประกอบตัวกลางสำหรับสารดังกล่าว
TH75305A (th) อนุพันธ์ 7-ฟีนิลอะมิโน-4-ควิโนโลน-3-คาร์บอกซิลิคแอซิด, กรรมวิธีสำหรับการเตรียมสารเหล่านี้ และการใช้สารเหล่านี้เป็นยา

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties